Effect of placebo conditions on polysomnographic parameters in primary insomnia: A meta-analysis

Sleep

Volumn 38, Issue 6, 2015, Pages 925-931

  Winkler, Alexander ^a   Rief, Winfried ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Insomnia; Meta analysis; Placebo; Polysomnographic; Review; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; HORMONE; HYPNOTIC AGENT; MELATONIN RECEPTOR AGONIST; NARCOTIC AGENT; NEUROPEPTIDE; PLACEBO; PROGESTERONE RECEPTOR; VALERIAN;

ARTICLE; DRUG RESPONSE; HUMAN; INTERRATER RELIABILITY; META ANALYSIS; PLACEBO EFFECT; POLYSOMNOGRAPHY; PRIMARY INSOMNIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SLEEP QUALITY; SLEEP TIME; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; AGED; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; WAKEFULNESS;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; POLYSOMNOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; WAKEFULNESS;

EID: 84931057785     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.4742     Document Type: Article

References (69)

1. th edition, text revision. Washington, DC: American Psychiatric Association, 2000.
2. Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and related health problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: Results from the America Insomnia Survey. Biol Psychiatry 2011;69:592-600.
3. th edition. Arlington, VA: American Psychiatric Publishing, 2013.
4. Leger D, Poursain B, Neubauer D, Uchiyama M. An international survey of sleeping problems in the general population. Curr Med Res Opin 2008;24:307-17.
5. Winkler A, Auer C, Doering B, Rief W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs 2014;28:799-816.
6. Buysse DJ. Insomnia. JAMA 2013;309:706-16.
7. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012;345.
8. Siriwardena A, Apekey T, Tilling M, Dyas JV, Middleton H, Orner R. General practitioners' preferences for managing insomnia and opportunities for reducing hypnotic prescribing. J Eval Clin Pract 2010;16:731-7.
9. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169-73.
10. Mora MS, Nestoriuc Y, Rief W. Lessons learned from placebo groups in antidepressant trials. Philos Trans R Soc Lond B Biol Sci 2011;366:1879-88.
11. McCall WV, D'Agostino R, Dunn A. A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med 2003;4:57-62.
12. Belanger L, Vallieres A, Ivers H, Moreau V, Lavigne G, Morin CM. Meta-analysis of sleep changes in control groups of insomnia treatment trials. J Sleep Res 2007;16:77-84.
13. JARS. Reporting standards for research in psychology: why do we need them? What might they be? Am Psychol 2008;63:839-51.
14. Glass G. Primary, secondary and meta-analysis of research. Health Educ Res 1976;5:3-8.
15. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
16. Borenstein M, Hedges L, Higgins J, Rothstein H. Comperhensive meta-analysis, version 2. Engelwood, NJ: Biostat Inc., 2005.
17. Hedges LV, Olkin I. Nonparametric estimators of effect size in meta-analysis. Psychol Bull 1984;96:573-80.
18. nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates Inc, 1988.
19. Rosenthal R. Meta-analytic procedures for social research. Newbury Park, CA: Sage Publications, 1993.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
21. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. Chichester, UK: Wiley, 2009.
22. Hedges LV, Vevea JL. Fixed- and random-effects models in metaanalysis. Psychol Methods 1998;3:486-504.
23. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention & Treatment 1998;1(2).
24. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63.
25. Johnson BT, Eagly AH. Quantitative synthesis of social psychological research. In: Reis HT, Judd CM, eds. Handbook of research methods in social and personality psychology. London: Cambridge University Press, 2000:496-528.
26. Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology 1992;26:193-7.
27. Buckley T, Duggal V, Schatzberg AF. The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: a pilot study. J Clin Sleep Med 2008;4:235-41.
28. Fleming J, Moldofsky H, Walsh JK, Scharf M, Nino MG, Radonjic D. Comparison of the residual effects and efficacy of short term zolpidem, flurazepam and placebo in patients with chronic insomnia. Clin Drug Invest 1995;9:303-13.
29. Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J ClinPsychiatry 2001;62:453-63.
30. Herrmann WM, Kubicki ST, Boden S, Eich FX, Attali P, Coquelin JP. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation. J Intern Med Res 1993;21:306-22.
31. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010;33:1553-61.
32. Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 2011;34:1433-42.
33. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009;24:239-49.
34. Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009;32:351-60.
35. McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006;22:1633-42.
36. Monti JM, Alvarino F, Monti D. Conventional and power spectrum analysis of the effects of zolpidem on sleep EEG in patients with chronic primary insomnia. Sleep 2000;23:1075-84.
37. Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia - a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994;27:166-75.
38. Monti JM, Monti D, Estevez F, Giusti M. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. International Clin Psychopharmacol 1996;11:255-63.
39. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281:991-9.
40. Morin CM, Koetter U, Bastien C, Ware JC, Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005;28:1465-71.
41. Randall S, Roehrs TA, Roth T. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep 2012;35:1551-7.
42. Riemann D, Voderholzer U, Cohrs S, et al. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Trimipramin bei primaerer Insomnie: Ergebnisse einer polysomnographischen kontrollierten Doppel-Blind-Studie. Pharmacopsychiatry 2002;35:165-74.
43. Roth T, Soubrane C, Titeux L, Walsh JK. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7:397-406.
44. Roth T, Wright KP, Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep 2006;29:335-41.
45. Roth TG, Roehrs TA, Koshorek GL, Greenblatt DJ, Rosenthal LD. Hypnotic effects of low doses of quazepam in older insomniacs. J Clin Psychopharmacol 1997;17:401-6.
46. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-9.
47. Schulz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers - a pilot-study. Pharmacopsychiatry 1994;27:147-51.
48. Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006;295:2851-8.
49. Walsh JK, Perlis M, Rosenthal M, Krystal A, Jiang J, Roth T. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med 2006;2:35-41.
50. Walsh JK, Salkeld L, Knowles LJ, Tasker T, Hunneyball IM. Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness. Sleep Med 2010;11:23-30.
51. Walsh JK, Soubrane C, Roth T. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry 2008;16:44-57.
52. Walsh JK, Vogel GW, Scharf M, et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000;1:41-9.
53. Ware J, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol 1997;20:116-25.
54. Wu RG, Bao JF, Zhang CA, Deng J, Long CL. Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological therapy for chronic insomnia. Psychother Psychosom 2006;75:220-8.
55. Xu ZQ, Jiang XJ, Li W, Gao D, Li XJ, Liu J. Propofol-induced sleep: efficacy and safety in patients with refractory chronic primary insomnia. Cell Biochem Biophys 2011;60:161-6.
56. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3:495-504.
57. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-91.
58. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
59. de la Fuente-Fernández R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001;293:1164-6.
60. Lidstone SC, Schulzer M, Dinelle K, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010;67:857-65.
61. Preston RA, Materson BJ, Reda DJ, Williams DW. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study. Arch Intern Med 2000;160:1449-54.
62. McCall W, D'Agostino R Jr, Rosenquist PB, et al. Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs. Sleep Med 2011;12:557-64.
63. McCall WV, Perlis ML, Xu T, Groman AE, Krystal A, Walsh JK. A comparison of placebo and no-treatment during a hypnotic clinical trial. Int J Clin Pharmacol Ther 2005;43:355-9.
64. Perlis ML, McCall WV, Jungquist CR, Pigeon WR, Matteson SE. Placebo effects in primary insomnia. Sleep Med Rev 2005;9:381-9.
65. Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 2013;12:191-204.
66. Doering BK, Rief W. Utilizing placebo mechanisms for dose reduction in pharmacotherapy. Trends Pharmacol Sci 2012;33:165-72.
67. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005;34:215-20.
68. Morin C, Belanger L, LeBlanc M, et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med 2009;169:447-53.
69. Enck P, Klosterhalfen S. The placebo response in clinical trials-the current state of play. Complement Ther Med 2013;21:98-101.